SynCore Biotechnology Co Ltd (4192) - Net Assets

Latest as of September 2025: NT$257.97 Million TWD ≈ $8.13 Million USD

Based on the latest financial reports, SynCore Biotechnology Co Ltd (4192) has net assets worth NT$257.97 Million TWD (≈ $8.13 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$272.85 Million ≈ $8.60 Million USD) and total liabilities (NT$14.88 Million ≈ $468.77K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SynCore Biotechnology Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	NT$257.97 Million
% of Total Assets	94.55%
Annual Growth Rate	-11.02%
5-Year Change	-47.43%
10-Year Change	N/A
Growth Volatility	23.73

SynCore Biotechnology Co Ltd - Net Assets Trend (2015–2024)

This chart illustrates how SynCore Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of SynCore Biotechnology Co Ltd for the complete picture of this company's asset base.

Annual Net Assets for SynCore Biotechnology Co Ltd (2015–2024)

The table below shows the annual net assets of SynCore Biotechnology Co Ltd from 2015 to 2024. For live valuation and market cap data, see SynCore Biotechnology Co Ltd (4192) market capitalisation.

Year	Net Assets	Change
2024-12-31	NT$294.69 Million ≈ $9.28 Million	-17.49%
2023-12-31	NT$357.14 Million ≈ $11.25 Million	+43.42%
2022-12-31	NT$249.01 Million ≈ $7.85 Million	-43.78%
2021-12-31	NT$442.92 Million ≈ $13.95 Million	-20.99%
2020-12-31	NT$560.58 Million ≈ $17.66 Million	-8.41%
2019-12-31	NT$612.03 Million ≈ $19.28 Million	-13.40%
2018-12-31	NT$706.70 Million ≈ $22.26 Million	-1.93%
2017-12-31	NT$720.61 Million ≈ $22.70 Million	-25.43%
2016-12-31	NT$966.36 Million ≈ $30.45 Million	+14.66%
2015-12-31	NT$842.81 Million ≈ $26.55 Million	--

Equity Component Analysis

This analysis shows how different components contribute to SynCore Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 12787300000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	NT$348.97 Million	118.42%
Total Equity	NT$294.69 Million	100.00%

SynCore Biotechnology Co Ltd Competitors by Market Cap

The table below lists competitors of SynCore Biotechnology Co Ltd ranked by their market capitalization.

Company	Market Cap
Sintercom India Limited NSE:SINTERCOM	$21.72 Million
Global SM Tech Limited KQ:900070	$21.73 Million
Giyani Metals Corp V:EMM	$21.73 Million
Jullundur Motor Agency (Delhi) Limited NSE:JMA	$21.74 Million
NEVADA LITHIUM RESOURCES F:87K	$21.70 Million
WITTED MEGACORP OYJ EO 1 F:8OS	$21.70 Million
Galileo Mining Ltd AU:GAL	$21.67 Million
Advicenne PA:ALDVI	$21.67 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in SynCore Biotechnology Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 357,136,000 to 294,688,000, a change of -62,448,000 (-17.5%).
Net loss of 54,283,000 reduced equity.
Other factors decreased equity by 8,165,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	NT$-54.28 Million	-18.42%
Other Changes	NT$-8.16 Million	-2.77%
Total Change	NT$-	-17.49%

Book Value vs Market Value Analysis

This analysis compares SynCore Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.34x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 1.90x to 2.34x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	NT$10.31	NT$19.60	x
2018-12-31	NT$8.48	NT$19.60	x
2019-12-31	NT$6.29	NT$19.60	x
2020-12-31	NT$19.84	NT$19.60	x
2021-12-31	NT$14.36	NT$19.60	x
2022-12-31	NT$8.10	NT$19.60	x
2023-12-31	NT$11.14	NT$19.60	x
2024-12-31	NT$8.38	NT$19.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently SynCore Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -18.42%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -232.60%
• Asset Turnover: 0.07x
• Equity Multiplier: 1.08x
Recent ROE (-18.42%) is above the historical average (-46.22%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	-21.61%	-1178.09%	0.02x	1.22x	NT$-266.44 Million
2016	-16.79%	-2351.97%	0.01x	1.15x	NT$-258.87 Million
2017	-35.80%	-3167.89%	0.01x	1.17x	NT$-330.05 Million
2018	-41.62%	-3816.86%	0.01x	1.14x	NT$-364.80 Million
2019	-66.77%	-3151.36%	0.02x	1.25x	NT$-469.84 Million
2020	-71.16%	-2991.29%	0.01x	1.63x	NT$-454.98 Million
2021	-103.54%	-6608.98%	0.01x	1.86x	NT$-502.89 Million
2022	-75.77%	-1189.80%	0.04x	1.75x	NT$-213.57 Million
2023	-10.69%	-189.01%	0.05x	1.06x	NT$-73.89 Million
2024	-18.42%	-232.60%	0.07x	1.08x	NT$-83.75 Million

Industry Comparison

This section compares SynCore Biotechnology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $1,782,670,400
Average return on equity (ROE) among peers: 2.91%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
SynCore Biotechnology Co Ltd (4192)	NT$257.97 Million	-21.61%	0.06x	$21.71 Million
Apex Biotechnology Corp (1733)	$1.35 Billion	29.84%	0.15x	$89.90 Million
Sinphar Pharmaceutical Co Ltd (1734)	$3.42 Billion	0.26%	0.72x	$188.76 Million
Panion & BF Biotech Inc (1760)	$2.01 Billion	9.08%	0.54x	$184.23 Million
Chunghwa Chemical Synthesis & Biotech Co Ltd (1762)	$3.36 Billion	1.58%	0.42x	$68.46 Million
SYN-Tech Chem & Pharm Co Ltd (1777)	$996.24 Million	6.00%	0.56x	$99.61 Million
Level Biotechnology (3118)	$522.28 Million	13.08%	0.40x	$34.35 Million
GenMont Biotech Inc (3164)	$290.14 Million	-2.84%	0.08x	$47.96 Million
Medigen Biotechnology (3176)	$3.54 Billion	-16.06%	0.36x	$144.62 Million
Sagittarius Life Science (3205)	$965.47 Million	-11.83%	0.10x	$119.60 Million
Genovate Biotechnology Co Ltd (4130)	$1.38 Billion	0.03%	0.10x	$98.37 Million

About SynCore Biotechnology Co Ltd

TWO:4192 Taiwan Biotechnology

Market Cap

$21.71 Million

NT$689.23 Million TWD

Market Cap Rank

#24789 Global

#1552 in Taiwan

Share Price

NT$19.60

Change (1 day)

-1.75%

52-Week Range

NT$19.55 - NT$30.35

All Time High

NT$537.12